Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ioglycamic acid is a triiodinated, ionic radiopaque contrast medium belonging to the class of triiodobenzene derivatives. It was primarily developed for use in intravenous cholangiography and cholecystography to visualize the gallbladder and biliary tract. The drug is characterized by its dual excretion pathway, being eliminated through both the bile and the urine, with hepatic transport occurring via an active process. While it was widely used in the 1970s and 1980s under brand names like Biligram and Bilivistan, its clinical application has significantly declined due to the development of safer non-ionic contrast agents and the advent of non-invasive imaging techniques such as ultrasonography and magnetic resonance cholangiopancreatography (MRCP). Experimental uses have included inhalation bronchography using a powdered form and hepatobiliary scintiscanning when labeled with Iodine-131.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ioglycamic acid.